DRUG · Mapped RxNorm record
Lurbinectedin
Normalized identity: lurbinectedinView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
NCT06496048
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Irinotecan
Normalized identity: irinotecanView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Lurbinectedin
Normalized identity: lurbinectedinView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Topotecan
Normalized identity: topotecanView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedLurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Relapsed Small Cell Lung Cancerunresolved
Interventions
LurbinectedinDRUG · verified · RxNorm: lurbinectedin
IrinotecanDRUG · verified · RxNorm: irinotecan
LurbinectedinDRUG · verified · RxNorm: lurbinectedin
TopotecanDRUG · verified · RxNorm: topotecan
Sponsors & collaborators
Luye Pharma Group Ltd.lead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06496048 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.